Get startedLog in
    Picture of Travere Therapeutics logo

    TVTX — Travere Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapHigh Flyer
    All News

    Brief: Travere Therapeutics Provides Corporate Update And 2026 Outlook

    Picture of Travere Therapeutics logoTravere Therapeutics
    12/01/2026 22:39
    Jan 12 (Reuters) - Travere Therapeutics Inc TVTX.O:

TRAVERE THERAPEUTICS PROVIDES CORPORATE UPDATE AND 2026 OUTLOOK

TRAVERE THERAPEUTICS INC - EXPECTS $127 MILLION U.S. NET PRODUCT SALES IN Q4 2025

TRAVERE THERAPEUTICS INC - EXPECTS $410 MILLION U.S. NET PRODUCT SALES FOR 2025

TRAVERE THERAPEUTICS INC - TO RESTART PHASE 3 HARMONY STUDY IN Q1 2026

TRAVERE THERAPEUTICS INC - PDUFA TARGET DATE FOR FILSPARI APPROVAL IS JANUARY 13, 2026

Source text: ID:nBw1kCM89a

Further company coverage: TVTX.O

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Travere Therapeutics

    See all news